Table 1 Summary of previous reports of patients with thyroid carcinoma and nephrotic syndrome
From: Minimal change disease with papillary thyroid carcinoma: a report of two adult cases
Author/ reference | Sex | Age | TC | Renal pathology | Time of NS (before or after TC) | Treatment | NS response | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Carcinoma | NS | ||||||||||
Koopman et al. [4] | F | 52 | MTC | AAG | After/7years | Surgery, radiation | ACEI | PR | |||
Han et al. [5] | F | 44 | PTC | MPGN | Concidence | Surgery | Steroids | CR | |||
Pattanashetti et al. [6] | M | 14 | PTC | MPGN | Concidence | Surgery | ACEI | CR | |||
Liu et al. [8] | M | 11 | PTC | MCD | Before/80days | Surgery | Steroids | CR | |||
Tabar et al. [7] | F | 21 | PTC | FSGS | Before/13months | Surgery radiation | Steroids hemodialysis | Follow up | |||
Cai et al. [9] | F | 38 | PTC | MCD | Concidence | Surgery | CR | ||||
Yang et al. [11] | M | 56 | PTC | NS | After/2years | Lenvatinib(20 mg/day) to sorafenib(400 mg/day) | PR | ||||
Present patient 1 | F | 35 | PTC | MCD | Concidence | surgery, radiation | Steroids | CR | |||
Present patient 2 | M | 50 | PTC | MCD | After/3years | Surgery, radiation | Tacrolimus, riruximab | CR | |||